Literature DB >> 17366916

[Brain and spinal cord preconditioning for the protection against ischemic injury].

Mishiya Matsumoto1, Kazuyoshi Ishida, Takefumi Sakabe.   

Abstract

Recent studies have suggested that the brain preconditioning could induce tolerance to ischemia in humans. It has been believed that newly synthesized proteins are required for the acquisition of delayed tolerance in the brain and spinal cord. However, the mechanism other than the synthesis of neuroprotective proteins may also play a pivotal role. Preconditioning may reprogram the response to ischemic injury as seen during hibernation. Preconditioning with hyperbaric oxygen, volatile anesthetics, and xenon seems to be the focus of the attention from the standpoint of the clinical setting. Strong neuroprotection by the preconditioning with isoflurane and xenon is reported in animal experiments and may change the traditional idea of neuroprotection by anesthetics. The discovery that erythropoietin exerts neuroprotective properties has opened new therapeutic avenues. Erythropoietin is induced in the brain by hypoxic preconditioning and by the pharmacological preconditioning. In addition, the intravenous administration of erythropoietin has been shown to be safe and beneficial for acute stroke in humans. Therefore, erythropoietin is now one of the most promising neuroprotective agents. The research in the brain and spinal cord preconditioning will contribute to the elucidation of the mechanism of ischemic injury and to the establishment of new therapies for neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17366916

Source DB:  PubMed          Journal:  Masui        ISSN: 0021-4892


  1 in total

1.  Neuroprotective effect of combined hypoxia-induced VEGF and bone marrow-derived mesenchymal stem cell treatment.

Authors:  Sung Su An; Hong Lian Jin; Keung Nyun Kim; Dong Seok Kim; Joon Cho; Meng-Lu Liu; Jin Soo Oh; Do Heum Yoon; Min Hyung Lee; Yoon Ha
Journal:  Childs Nerv Syst       Date:  2010-03       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.